Circunited BioPharma

Circunited (Jiuke Runjia) is a biotechnology company specializing in the development of next-generation in vivo CAR-T therapies for autoimmune diseases and hematological malignancies. The company's lead candidate, Arnovie101, utilizes a proprietary mRNA-LNP delivery platform called ArnoVec to generate CD19-targeting CAR-T cells directly within the patient's body. This innovative approach eliminates the need for ex vivo cell manufacturing, lymphodepletion, and immunosuppressive pre-conditioning, potentially offering a safer and more accessible alternative to traditional CAR-T therapies. Circunited has demonstrated promising clinical results for Arnovie101 in patients with severe refractory systemic lupus erythematosus (SLE), showing rapid B cell depletion and significant disease activity reduction.